Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str

Verify with FDA CVM →

133 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
133
Total Reports
25
Deaths Reported
1880.0%
Death Rate

Active Ingredients

Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str

Administration Routes

Subcutaneous

Species Affected

Cat 133

Most Affected Breeds

Domestic Shorthair 88
Domestic Longhair 9
Siamese 7
Domestic Mediumhair 7
Persian 6
Ragdoll 4
Maine Coon 3
Bengal 2
Cat (other) 2
Norwegian Forest 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 75
Anorexia 57
Fever 51
Weight loss 28
Other abnormal test result NOS 25
Vomiting 20
Dehydration 19
Abnormal radiograph finding 17
Febrile 15
Death by euthanasia 15
Anaemia NOS 15
Decreased appetite 15

Outcome Breakdown

Ongoing
69 (50.7%)
Recovered/Normal
37 (27.2%)
Euthanized
15 (11.0%)
Died
10 (7.4%)
Outcome Unknown
5 (3.7%)

Data Summary

Metric Value
Total adverse event reports 133
Reports involving death 25
Case-fatality rate (reported events) 1880.0%
Distinct species in reports 1
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 133 adverse event reports referencing Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str, including 25 reports in which the animal died — a 1880.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str. Reported administration route is Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str reports are Cat (133 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (88), Domestic Longhair (9), Siamese (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str are Lethargy (see also Central nervous system depression in 'Neurological') (75), Anorexia (57), Fever (51), Weight loss (28). Of the 136 reports with a coded outcome, Ongoing is the leading category at 50.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Calicivirus, Strain F-9, Passage 7, Lot A; Feline Chlamydia Psittaci, Str.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial